Pentwater Capital Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Pentwater Capital Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-17,694	Closed	-$408K	–	411
2020 Q4	$408K	Buy	+17,694	New	+$224K	﹤0.01%	206

Pentwater Capital Management's PRVL Position: Q1 2021 in Review

Pentwater Capital Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 17,694 shares — an estimated $408K sold.

Pentwater Capital Management first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $408K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Pentwater Capital Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Pentwater Capital Management sold 17,694 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $408K.
Pentwater Capital Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Pentwater Capital Management's Prevail Therapeutics Inc. Common Stock position peaked at $408K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Pentwater Capital Management's 13F filing for Q1 2021, filed 17 May 2021.